^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    pan-EGFR inhibitor

    Related drugs:
    Apply
    Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC (NCI-2017-00831) (NCT03066206)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    05/24/2024
    Initiation :
    03/17/2017
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    EGFR • HER-2
    |
    EGFR mutation • EGFR exon 20 insertion • HER-2 exon 20 insertion • HER-2 L755S • HER-2 A775_G776insYVMA • HER-2 V777L • EGFR exon 20 mutation • HER-2 A775 • HER-2 P780-Y781insGSP • HER-2 YVMA • HER-2 exon 19 mutation • HER-2 exon 23 mutation
    |
    Pozenveo (poziotinib)
    A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations (PINNACLE) (NCT05378763)
    Phase 3
    Spectrum Pharmaceuticals, Inc
    Suspended
    Last update posted :
    02/15/2024
    Initiation :
    05/12/2022
    Primary completion :
    12/25/2027
    Completion :
    12/25/2028
    HER-2
    |
    HER-2 mutation • HER-2 exon 20 mutation • HER-2 exon 23 mutation
    |
    docetaxel • Pozenveo (poziotinib)
    Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer (NCT05045404)
    Phase 2
    M.D. Anderson Cancer Center
    Withdrawn
    Last update posted :
    09/13/2023
    Initiation :
    06/16/2021
    Primary completion :
    02/02/2023
    Completion :
    02/02/2023
    EGFR
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Cyramza (ramucirumab) • Pozenveo (poziotinib)
    A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway (NCT02544997)
    Phase 2
    Samsung Medical Center
    Completed
    Last update posted :
    07/07/2020
    Initiation :
    09/01/2015
    Primary completion :
    02/01/2020
    Completion :
    02/01/2020
    EGFR • HER-2
    |
    EGFR mutation • HER-2 amplification • EGFR expression • EGFR overexpression • AR expression
    |
    Pozenveo (poziotinib)
    Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001) (NCT02979821)
    Phase 2
    Korean Association for the Study of Targeted Th...
    Completed
    Last update posted :
    05/24/2018
    Initiation :
    10/01/2016
    Primary completion :
    12/01/2017
    Completion :
    12/01/2017
    HER-2
    |
    HER-2 mutation
    |
    Pozenveo (poziotinib)